ArticleFrontiers in immunology2026
The evaluation of cytokine profiles in atopic dermatitis patients treated with dupilumab: association with ocular complications.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis (AD), yet a substantial proportion of patients develop ocular complications collectively termed dupilumab-associated ocular surface disease (DAOSD). Despite multiple proposed mechanisms - including goblet cell depletion, mucin deficiency, Th1/Th17 immune shifts, and microbiome alterations - no upstream epithelial cytokine marker has been clearly identified. Objective: To evaluate whether plasma cytokines differ between AD patients treated with dupilumab who develop ocular complications and those without ocular involvement. Methods: Complex dermatological examination was performed in adult AD patients receiving dupilumab for ≥24 months. Plasma cytokines (IFN-γ, TNF-α, IL-23, IL-2, IL-31, IL-6, IL-17A, IL-17E, IL-12p70, TSLP, IL-4, IL-5, IL-13, IL-10, IL-33) were quantified under unstimulated and PMA/ionomycin-stimulated conditions in winter and summer seasons. Differences between groups were assessed using non-parametric tests (Mann-Whitney U test and Kolmogorov-Smirnov test). To account for multiple comparisons across the large number of tested cytokines, false discovery rate (FDR) correction was performed using the Benjamini-Hochberg procedure with a significance threshold of q = 0.05. Receiver operating characteristic (ROC) analysis was performed to evaluate biomarker potential to explore potential discriminative performance. AUC values were calculated using empirical (non-parametric) ROC analysis. Results: During the summer period, stimulated thymic stromal lymphopoietin (TSLP) levels were nominally higher in patients with ocular complications compared with those without (p = 0.045). However, this difference did not remain statistically significant after FDR correction. In winter, stimulated TSLP showed a non-significant trend toward higher levels (p = 0.088). No other cytokines differed between groups. ROC analysis demonstrated moderate discriminative ability of stimulated TSLP (AUC 0.81 in summer; 0.70 in winter), although confidence intervals were wide. Conclusion: Stimulated TSLP may represent a preliminary observation requiring confirmation in dupilumab-treated AD patients with ocular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.